Literature DB >> 10862711

Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex.

A A Hack1, M Y Lam, L Cordier, D I Shoturma, C T Ly, M A Hadhazy, M R Hadhazy, H L Sweeney, E M McNally.   

Abstract

Sarcoglycan is a multimeric, integral membrane glycoprotein complex that associates with dystrophin. Mutations in individual sarcoglycan subunits have been identified in inherited forms of muscular dystrophy. To evaluate the contributions of sarcoglycan and dystrophin to muscle membrane stability and muscular dystrophy, we compared muscle lacking specific sarcoglycans or dystrophin. Here we report that mice lacking (delta)-sarcoglycan developed muscular dystrophy and cardiomyopathy similar to mice lacking (gamma)-sarcoglycan. However, unlike muscle lacking (gamma)-sarcoglycan, (delta)-sarcoglycan-deficient muscle was sensitive to eccentric contraction-induced disruption of the plasma membrane. In the absence of (delta)-sarcoglycan, (alpha)-, (beta)- and (gamma)-sarcoglycan were undetectable, while dystrophin was expressed at normal levels. In contrast, without (gamma)-sarcoglycan, reduced levels of (alpha)-, (beta)- and (delta)-sarcoglycan were expressed, glycosylated and formed a complex with each other. Thus, the elimination of (gamma)- and (delta)-sarcoglycan had different molecular consequences for the assembly and function of the dystrophin-glycoprotein complex. Furthermore, these molecular differences were associated with different mechanical consequences for the muscle plasma membrane. Through this in vivo analysis, a model for sarcoglycan assembly is proposed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10862711     DOI: 10.1242/jcs.113.14.2535

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  84 in total

Review 1.  M-band: a safeguard for sarcomere stability?

Authors:  Irina Agarkova; Elisabeth Ehler; Stephan Lange; Roman Schoenauer; Jean-Claude Perriard
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

2.  Distinguishing the 4qA and 4qB variants is essential for the diagnosis of facioscapulohumeral muscular dystrophy in the Chinese population.

Authors:  Zhi-Qiang Wang; Ning Wang; Silvere van der Maarel; Shen-Xing Murong; Zhi-Ying Wu
Journal:  Eur J Hum Genet       Date:  2010-08-25       Impact factor: 4.246

3.  Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle.

Authors:  Karen A Lapidos; Yiyin E Chen; Judy U Earley; Ahlke Heydemann; Jill M Huber; Marcia Chien; Averil Ma; Elizabeth M McNally
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

4.  Translating mighty mice into neuromuscular therapeutics: is bigger muscle better?

Authors:  Eric P Hoffman; Diana Escolar
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

5.  Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle.

Authors:  Sanjeewa A Goonasekera; Chi K Lam; Douglas P Millay; Michelle A Sargent; Roger J Hajjar; Evangelia G Kranias; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

Review 6.  Progress in gene therapy of dystrophic heart disease.

Authors:  Y Lai; D Duan
Journal:  Gene Ther       Date:  2012-02-09       Impact factor: 5.250

7.  Enhanced Ca²⁺ influx from STIM1-Orai1 induces muscle pathology in mouse models of muscular dystrophy.

Authors:  Sanjeewa A Goonasekera; Jennifer Davis; Jennifer Q Kwong; Federica Accornero; Lan Wei-LaPierre; Michelle A Sargent; Robert T Dirksen; Jeffery D Molkentin
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

8.  Thrombospondin expression in myofibers stabilizes muscle membranes.

Authors:  Davy Vanhoutte; Tobias G Schips; Jennifer Q Kwong; Jennifer Davis; Andoria Tjondrokoesoemo; Matthew J Brody; Michelle A Sargent; Onur Kanisicak; Hong Yi; Quan Q Gao; Joseph E Rabinowitz; Talila Volk; Elizabeth M McNally; Jeffery D Molkentin
Journal:  Elife       Date:  2016-09-26       Impact factor: 8.140

9.  Cytoplasmic gamma-actin expression in diverse animal models of muscular dystrophy.

Authors:  Laurin M Hanft; Daniel J Bogan; Ulrike Mayer; Stephen J Kaufman; Joe N Kornegay; James M Ervasti
Journal:  Neuromuscul Disord       Date:  2007-05-01       Impact factor: 4.296

10.  Null mutation of gp91phox reduces muscle membrane lysis during muscle inflammation in mice.

Authors:  Hal X Nguyen; James G Tidball
Journal:  J Physiol       Date:  2003-10-10       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.